Compare CBFV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBFV | CRBU |
|---|---|---|
| Founded | 1901 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.9M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | CBFV | CRBU |
|---|---|---|
| Price | $35.66 | $1.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $35.50 | $10.00 |
| AVG Volume (30 Days) | 5.1K | ★ 1.2M |
| Earning Date | 01-27-2026 | 03-09-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $40,244,000.00 | $9,295,000.00 |
| Revenue This Year | $12.14 | N/A |
| Revenue Next Year | $14.91 | $5.37 |
| P/E Ratio | $72.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.01 | $0.66 |
| 52 Week High | $37.75 | $3.54 |
| Indicator | CBFV | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 48.32 |
| Support Level | $34.41 | $1.47 |
| Resistance Level | $37.50 | $1.64 |
| Average True Range (ATR) | 0.52 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 62.57 | 47.22 |
CB Financial Services Inc operates as a bank holding company. The company conducts its operations through its wholly-owned subsidiary, Community Bank, a Pennsylvania-chartered commercial bank. The Bank offers products and services related to residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a range of deposit products for individuals and businesses in its market area. It operates in two operating units namely Community Banking and Insurance brokerage service segment. The bank generates its revenue in the form of interest.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.